Skip to main content
Select Search Option
Menu
Weill Cornell Medicine
  • Weill Cornell Medicine
  • Care
  • Discover
  • Teach
Myeloma Center
Myeloma Center
Explore this Website
  • Home
  • About Us
    • Our Team
  • For Patients
    • About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
    • Multiple Myeloma
    • Amyloidosis
    • Other Plasma Cell Disorders
    • Myeloma Signs and Symptoms
    • Amyloidosis Signs and Symptoms
    • Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
    • Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
    • Multiple Myeloma and Plasma Cell Disorder Treatment
    • Understanding and Managing Side Effects
    • Your First Visit
      • Self-Referral
    • Support Groups and Helpful Links
    • Frequently Asked Questions
  • Referring Physicians
    • Refer a Patient
  • Research and Clinical Trials
    • Basic and Translational Research
    • Bibliography
  • Contact Us
  • Weill Cornell Medicine
  • Care
  • Discover
  • Teach
  • Home
  • About Us
  • For Patients
  • Referring Physicians
  • Research and Clinical Trials
  • Contact Us
  • Home
  • Bibliography
    • Basic and Translational Research
    • Bibliography

Bibliography

Found 5 results
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
Kwon D, Niesvizky R.  2013.  Treatment of multiple myeloma with carfilzomib in patients with renal injury.. Clin Adv Hematol Oncol. 11(9):605-6.
Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui A-M, Gupta N, Di Bacco A, Yu J et al..  2014.  Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.. Blood. 124(7):1047-55.
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al..  2014.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.
Krishnan U, Mark TM, Niesvizky R, Sobol I.  2015.  Pulmonary hypertension complicating multiple myeloma.. Pulm Circ. 5(3):590-7.
Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM.  2013.  Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.. Br J Haematol. 163(4):478-86.
Our Location
Myeloma Center
Contact Us
  • Twitter
  • Facebook
  • YouTube
425 East 61st St
8th Floor
New York, NY 10065
Phone: (646) 962-6500
Fax: (212) 746-8961
  • About Us
    • Our Team
  • For Patients
    • About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
    • Multiple Myeloma
    • Amyloidosis
    • Other Plasma Cell Disorders
    • Myeloma Signs and Symptoms
    • Amyloidosis Signs and Symptoms
    • Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
    • Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
    • Multiple Myeloma and Plasma Cell Disorder Treatment
    • Understanding and Managing Side Effects
    • Your First Visit
    • Support Groups and Helpful Links
    • Frequently Asked Questions
  • Referring Physicians
    • Refer a Patient
  • Research and Clinical Trials
    • Basic and Translational Research
    • Bibliography
  • Contact Us
Care. Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and individualized clinical care, making groundbreaking biomedical discoveries, and educating generations of exceptional doctors and scientists.
Weill Cornell Medicine NewYork - Presbyterian
© Weill Cornell Medicine.
  • Privacy & Legal
  • Careers
  • Giving
  • Directory
  • Web Accessibility Assistance